We report here that B-galactoside binding protein (BGBP), an antiproliferative cytokine which can program cancer cells to undergo apoptosis, exhibits equal therapeutic efficacy against cancer cells that display diverse mechanisms of drug resistance and against their parental cells. The mechanisms of drug resistance in the cancer cells that we have examined include overexpression of P-glycoprotein, increased efficiency of DNA repair, and altered expression and mutation in the topoisomerase I and II enzymes. We also report that BGBP exerted its effect by arresting the cells in S phase prior to the activation of programmed cell death. The uniquely similar profile of response to BGBP by these drug-resistant cells and their parental cells extends the therapeutic potential of this cytokine in the treatment of cancers and offers a promising alternative to patients whose tumors are refractory to the currently available cadre of chemotherapeutic agents. 
Introduction
The ability of cancer cells to develop intrinsic or acquired resistance to virtually every drug used in cancer chemotherapy is a major problem that leads to treatment failure. It is clear that multidrug resistance is not attributable to the overexpression of the ATP-binding cassette superfamily of transporters alone (1) . It is recognized that the emergence of drug resistance in cancer is a result of multiple genetic alterations during tumor progression, where changes in the expression of a large number of genes (2) contribute to drug resistance by virtue of their extended normal cellular functions in transport (3), metabolism (4) , and mitogenic and survival signaling (5) (6) (7) . Extensive clinical literature confirms that drug resistance is associated with poor prognosis and hence the development of novel anticancer drugs or agents that can circumvent or reverse multidrug resistance is essential in combating cancer effectively. We show here that h-galactoside binding protein (hGBP), an antiproliferative cytokine which negatively regulates the cell cycle and selectively induces apoptosis in cancer cells (8) (9) (10) (11) , extends its proapoptotic efficacy to cancer cells that have developed diverse mechanisms of drug resistance. Our results suggest that hGBP has potential application in the treatment and eradication of drug-resistant cancers.
Materials and Methods
Cell Lines. Drug-resistant oral carcinoma KB-V-1 (12), breast cancer MCF-7/D40 (13), ovarian cancer 2008/CP (14) , leukemia RERC (15) , and their corresponding parental cells were cultured in the appropriate media. The human colorectal carcinoma HT-29 cells had been infected with a retrovirus carrying the full-length cDNA for the human multidrug resistance gene, MDR1, which encodes P-glycoprotein, and then selected for resistance to vinblastine (16) . Dose-dependent studies were conducted to determine the sensitivity of each drug-resistant cell line to hGBP compared with their respective parental cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (17) . In brief, cells were plated the night before in the absence of the selecting drugs, exposed to various concentrations of hGBP for 72 hours, and followed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.
Cell Growth and Apoptosis. For cell replication kinetics, triplicate cultures in 5 cm Petri dishes were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum at 37jC in a humidified atmosphere of 5% CO 2 in air. DNA content for cell cycle analysis was done on cells washed twice in PBS-bovine serum albumin, examined under an inverted microscope, fixed in 70% ethanol at 4jC, washed and stained with 40 Ag/mL propidium iodide. Apoptosis was evaluated by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling assay using the Apo-BrdUrd kit (Phoenix Flow System, San Diego, CA, USA) as described previously (11) . Briefly, 1 Â 10 6 hGBP-treated or untreated cells were washed in PBS, fixed in 1% paraformaldehyde solution, washed, resuspended in ice-cold 70% ethanol, and stored at À20jC until use. For staining, samples were incubated for 60 minutes at 37jC with terminal deoxynucleotidyl transferase enzyme and FITC-dUTP. Cells were washed, resuspended in propidium iodide and RNase solution and incubated for 30 minutes at room temperature. Samples were analyzed in a FACS Calibur (Becton Dickinson, San Jose, CA) within 3 hours of staining.
Human Recombinant BGBP. The recombinant human hGBP (Hu-r-hGBP) was expressed in E. coli BL21 using the cDNA H-Gal-1 in pET21a (18) . The protein was purified by immunoaffinity chromatography using the immunoglobulin G fraction of monoclonal antibody clone B2 (8) .
Results
To determine the efficacy of Hu-r-hGBP on drug resistance, we used a panel of cancer cell lines that exhibit resistance to various chemotherapeutic agents. The drug-resistant cells include MCF-7/ D40, an MCF-7-derived cell line selected for resistance to doxorubicin that overexpresses P-glycoprotein as well as other factors that contribute to the multidrug resistance phenotype (13); 2008/CP, an ovarian carcinoma cell line selected for resistance to cisplatin that exhibits increased metallothionein gene expression and enhanced DNA repair as mechanisms of resistance (14); KB-V-1, a P-glycoprotein overexpressing cell line selected for resistance to vinblastine as well as being cross-resistant to several other anticancer drugs (12); HT-29/VMDR, a multidrug-resistant HT-29 colon carcinoma cell line infected with and overexpressing the full-length cDNA for P-glycoprotein (16) ; and RERC, a U937-derived leukemic cell line selected for sequential resistance to etoposide and camptothecin (15) . These cells were treated in parallel with their parental counterparts, either with the chemotherapeutic agents that they had been selected in (Fig. 1,  top) or with Hu-r-hGBP (Fig. 1, bottom) . Our results show that hGBP was equally efficient against both the parental and the drug-resistant cells regardless of their mechanisms of resistance. The IC 50 of hGBP for the drug-resistant cells were between 200 and 300 ng/mL, which corresponds to the inhibitory concentrations observed in previous studies with mammary cancer cells (9, 11) .
In previous studies, we have shown that the modalities by which hGBP exerts its anticancer effect involve inhibition of cell replication, cell cycle arrest in S phase, and consequent activation of apoptosis (9, 11, 19) . We therefore assessed rate of cell growth, cell cycle population distribution, and time of initiation and evolution of programmed cell death. Results in Fig. 2A and B show that hGBP induced dose-dependent inhibition of cell replication leading to growth arrest with a similar pattern both in MCF-7 and MCF-7/D40 cells. Terminal deoxynucleotidyl transferase-mediated nick end labeling and cell cycle analysis (Fig. 2C and D) show that the onset of apoptosis in the arrested cells became apparent at day 4 after the addition of hGBP and that apoptosis increased henceforth. Quantitation of apoptotic cells shows that there was a progressive evolution of the apoptotic process as function of time and shows that no measurable amount of cell death occurred from days 1 to 3 whereas the arrested cells accumulated in S phase (Fig. 2E and F,  inset b) . These results were confirmed in repeated experiments.
Similar effects on the induction of apoptosis by hGBP were observed in other drug-resistant cells and their parental counterparts (Table 1 ). In Fig. 2 , it is noteworthy that the multidrugresistant MCF-7/D40 cells were four times more sensitive to hGBP than their parental cells as a similar effect on inhibition of growth, S phase arrest and evolution of the apoptotic process were obtained with 50 to 100 ng/mL of hGBP instead of the 200 to 400 ng/mL required for the MCF-7 cells.
Discussion
The effectiveness of current cancer chemotherapeutic drugs is hampered by lack of specificity, systemic toxicity, rapid drug metabolism, and the development of either intrinsic or acquired drug resistance (20) . The effectiveness of drugs designed to target specific molecular lesions responsible for the deregulated growth of cancer cells is confounded and hampered by the multiplicity of lesions, which optimal agent to match to which lesion, toxicity, and resistance. In the present study, we have shown that hGBP exhibits equal therapeutic efficacy against cancer cells whether or not they have developed drug resistance. The cancer cells we have examined include those that overexpressed P-glycoprotein (MCF-7/D40, KB-V-1, and HT-29), those with increased DNA repair and metallothionein overexpression (2008/CP), and those with altered expression or mutation in the topoisomerase I (RERC) or II (MCF-7/D40 and RERC) enzymes. Significantly, the different mechanisms of drug resistance operating in these cells represent some of the most relevant causes of resistance in cancer known to date. The basis for the ability of hGBP to equally exert its proapoptotic effect regardless of the multiple genetic and biochemical changes, which in cancer cells fosters escape from therapeutic attack, is implicit, conceivably, with the nature and function of the hGBP molecule. Unlike conventional chemotherapeutic agents and drugs designed for molecular targeting, hGBP is a physiologically occurring antiproliferative cytokine. Secreted by CD4 + -and CD8 + -activated Tcells (10), hGBP is also endogenously released by somatic cells where it modulates cell cycle transition from S phase to G 2 -M (8). At cytostatic concentrations (20-400 ng/mL), the recombinant protein binds with high affinity (K d 10 À10 mol/L) to specific cell surface receptors to induce reversible S phase arrest in normal cells.
By contrast, in cancer cells, cell cycle arrest is followed by programmed cell death (9, 11, 19) , a pattern also observed in this study (Fig. 2) . Which molecular events regulated by hGBP are involved in S phase control in normal cells and in determining the shift from growth arrest to apoptosis in cancer cells is still under investigation. In previous work, we have shown that hGBP reduces Bcl-2 levels by shifting the Bcl-2/Bax ratio in favor of Bax (19) . Recently, we have reported a correlation between hGBP-induced cell cycle arrest and deregulated transactivation of the E2F1 transcription factor as a condition that can lead cancer cells into apoptosis (9) . Thus, apoptosis by hGBP could Figure 2 . Effects of hGBP on cell proliferation, cell cycle, and apoptosis. A and B, growth-response to Hu-r-hGBP according to dose (ng/mL) in MCF-7: 0 (.), 100 (E), 200 (x), and 400 (n); and in MCF-7/D40: 0 (.), 25 (E), 50 (x), and 100 (n). Data plotted are means of triplicate experiments. SE ranged from F 0.02 to F 0.54. Hu-r-hGBP added 3 hours after seeding. C and D, dual parameter terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling analysis from 20,000 events. Boxed areas, apoptotic cells and their relative percentages. Hu-r-hGBP, 400 ng/mL in MCF-7 cells and 100 ng/mL in MCF-7/D40 cells, added 3 hours after seeding. Data shown are from one representative experiment out of three. E and F, time of occurrence and pattern of progression of the apoptotic process in cells treated with Hu-r-hGBP (400 ng/mL in MCF-7, 100 ng/mL in MCF-7/D40) from 3 hours after seeding (filled columns ) and parallel untreated controls (open columns ). Data represent means of percentages of apoptotic cells from three separate experiments. Standard error ranged from F 0.07 to F 3.54. Insets, cell cycle distribution of DNA content assessed by fluorescence-activated cell sorting analysis at day 3, prior to the manifestation of apoptosis: a, cycling control cells; b, hGBP-arrested cells.
be initiated through modulation of existing apoptotic regulatory proteins and through transcription and translation-dependent changes to which normal and cancer cells respond differently. However, evidence is emerging that other pathways which regulate the cell growth/apoptosis equation can also be affected by hGBP. 3 It is conceivable that the exploitation of multiple proapoptotic pathways by hGBP adds to its ability to bypass drug resistance and provides a likely rationale, based on chance differences in molecular make-up, for the greater sensitivity to hGBP that drugresistant cells can have with respect to their parental cells (Fig. 2) .
Produced by activated T cells, hGBP is a naturally occurring molecule circulating in the healthy organism whose anticancer properties suggest a role in cancer surveillance and indicate a conceivably new mode by which immune cells may control malignancy. There are currently no chemotherapeutic drugs in the clinic that have the broad-spectrum of antitumor activity together with the ability to overcome multiple mechanisms of drug resistance as shown by hGBP. This suggests that hGBP offers a potentially safe and novel approach in cancer therapy which may be of particular benefit to patients who no longer respond to current chemotherapeutic treatments.
